Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093322 | 0.92 | CA1 (0.55) | ATMMAOBCA1CA2CA12 | |
| SCHEMBL255270 | 0.92 | CA1 (0.55) | ATMMAOBCA1CA2CA12 | |
| SCHEMBL28228661 | 0.79 | CA1 (0.55) | ATMMAOBCA1CA2CA12 | |
| SCHEMBL5486293 | 0.78 | GAA (0.45) | CA2TSHRLMNAGAAHPGD | |
| 1,2-Dimethoxybenzene SCHEMBL23113 | 0.78 | CA1 (0.77) | CA1CA2CA12CA4CA7 | |
| 1,2-Dimethoxybenzene SCHEMBL1796149 | 0.78 | CA1 (0.77) | CA1CA2CA12CA4CA7 | |
| SCHEMBL14925339 | 0.78 | RXRA (0.45) | MAOBLMNAGAARXRARXRB | |
| SCHEMBL10451316 | 0.78 | AR (0.49) | ATMMAOBCA1CA2CA12 | |
| SCHEMBL29749364 | 0.78 | AR (0.49) | ATMMAOBCA1CA2CA12 | |
| SCHEMBL8764659 | 0.76 | MAOB (0.44) | ATMMAOBCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MUTABILIS (FR) | 2019-05-28 | — | — | US | disclosed |
| EP-3110803-B1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2018-07-11 | — | — | EP | disclosed |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MUTABILIS (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-3110803-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Mutabilis (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| WO-2015128333-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| EP-2913330-A1 | Condensed derivatives of imidazole useful as pharmaceuticals | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876109-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2015-05-27 | — | — | EP | disclosed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PIK3CD, PIK3CA, MTOR | ATM 1836/4885MAOB 3333/4885CA1 3134/4885 |
| US-20170015661-A1 | HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | MSR1, IFNAR1, NOD2 | ATM 3107/4885MAOB 352/4885CA1 4017/4885 |
| US-10301305-B2 | Heteroaromatic derivatives and their use as pharmaceuticals | MSR1, IFNAR1, NOD2 | ATM 3107/4885MAOB 352/4885CA1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.